| ▲ | abeppu 7 days ago | |
From a study looking at cost-effectiveness of tafamidis: > Orphan drugs enjoy substantial pricing power because there are few or no therapeutic competitors. As a result, discounts off the list price, if any, tend to be small. In a recent study of 50 patients receiving tafamidis, the mean (SD) cost of a 30-day supply was $23,485 ($2); the resulting annual cost of $281,820 is greater than the $225,000 list price we assumed. In fact, U.S. prices for specialty pharmaceuticals typically experience substantial year-on-year price increases during the period of market exclusivity. I mean, we shouldn't be surprised what happens to prices when the law goes out of its way to create a monopoly. | ||